{"gene":"TRAF7","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2004,"finding":"TRAF7 was identified as a novel TRAF family member containing a RING finger domain, zinc finger domain, and seven WD40 repeats. It specifically interacted with MEKK3 and potentiated MEKK3-mediated AP1 and CHOP activation; depletion by antisense RNA inhibited this activation. Overexpression induced caspase-dependent apoptosis. Domain mapping showed TRAF7 uses distinct domains for MEKK3 signaling versus apoptosis induction.","method":"Co-immunoprecipitation, antisense RNA depletion, overexpression with reporter assays, domain mapping, caspase activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction shown, antisense knockdown with defined phenotype, domain mapping, and replicated across multiple orthogonal methods in a single focused study","pmids":["15001576"],"is_preprint":false},{"year":2005,"finding":"TRAF7 binds to the DNA-binding domain of c-Myb via its WD40 repeats and stimulates sumoylation of c-Myb at Lys-523 and Lys-499 (same sites as PIASy-induced sumoylation). TRAF7 has E3 ubiquitin ligase activity for self-ubiquitination. TRAF7 inhibited c-Myb-induced transactivation dependent on sumoylation sites. Overexpressed TRAF7 localizes to the cytoplasm and sequesters c-Myb and SUMO1 there, thereby negatively regulating c-Myb activity.","method":"Co-immunoprecipitation, domain mapping, sumoylation assay, transcriptional reporter assay, immunofluorescence/subcellular fractionation, mutagenesis of sumoylation sites","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro sumoylation assay with mutagenesis, Co-IP domain mapping, and functional transcriptional assay with sumoylation-site mutant controls","pmids":["16162816"],"is_preprint":false},{"year":2005,"finding":"Activation of TLR2 signaling induces activation of IKKs-IκBα and MKK3/6-p38 pathways not only through TRAF6 but also through TRAF7. CYLD tumor suppressor acts as a negative regulator of both TRAF6 and TRAF7, likely via a deubiquitination-dependent mechanism, forming an autoregulatory feedback loop controlling NF-κB-dependent inflammatory responses.","method":"Overexpression, reporter assays for NF-κB and p38 activation, TLR2 ligand stimulation (PGN, MALP-2, Pam3CSK4), cytokine measurement","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis via overexpression/reporter assays, single lab, two orthogonal readouts (IKK and p38 pathways)","pmids":["16230348"],"is_preprint":false},{"year":2011,"finding":"TRAF7 physically associates with NEMO (IKKγ) and p65/RelA. TRAF7 promotes Lys-29-linked polyubiquitination of both NEMO and p65, leading to their lysosomal degradation and repression of NF-κB transcriptional activity. TRAF7 also influences p65 nuclear distribution and promotes cell death.","method":"Co-immunoprecipitation, ubiquitination assays with K29-linkage-specific analysis, lysosomal inhibitor experiments, microarray expression analysis, cell death assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP, linkage-specific ubiquitination assay, lysosomal degradation rescue experiment, and transcriptomic validation in one study","pmids":["21518757"],"is_preprint":false},{"year":2010,"finding":"Traf7 is a direct transcriptional target of MyoD1 in muscle cells. Traf7 depletion accelerates myogenesis partly through downregulation of NF-κB activity. NEMO was identified as a Traf7-interacting protein by proteomic screen, and ubiquitylation of NEMO is regulated exclusively by Traf7 activity in myoblasts, coupling MyoD1 function to NF-κB activity.","method":"ChIP (MyoD1 binding to Traf7 promoter), siRNA depletion with myogenic differentiation assays, proteomic/co-IP screen identifying NEMO, ubiquitylation assays in myoblasts","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP for direct target identification, Co-IP interactome, ubiquitylation assay, and loss-of-function with defined cellular phenotype in one study","pmids":["20948544"],"is_preprint":false},{"year":2017,"finding":"Expression of mutant (but not wild-type) TRAF7 in vitro led to increased phosphorylation of NF-κB and increased expression of L1CAM, a marker of NF-κB pathway activation, demonstrating that adenomatoid tumor-associated TRAF7 WD40 domain mutations drive aberrant NF-κB pathway activation.","method":"In vitro expression of wild-type vs. mutant TRAF7, Western blot for p-NF-κB and L1CAM, immunohistochemistry","journal":"Modern pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, functional in vitro assay comparing WT vs. mutant, with IHC validation but limited mechanistic depth","pmids":["29148537"],"is_preprint":false},{"year":2019,"finding":"TRAF7 interacts with KLF4 protein via its N-terminus and promotes ubiquitin-mediated proteasomal degradation of KLF4, thereby promoting HCC cell migration and invasion. Restoration of KLF4 abrogated TRAF7-induced cell motility.","method":"Co-immunoprecipitation, ubiquitination assay, KLF4 overexpression rescue, migration/invasion assays in vitro and in vivo","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, and rescue experiment with defined cellular phenotype, single lab","pmids":["31730901"],"is_preprint":false},{"year":2019,"finding":"Robo4 binds to TRAF7 through interaction with the C-terminus of Robo4 in endothelial cells. TRAF7 is required for Robo4-mediated suppression of TNFα-induced vascular hyperpermeability and stabilization of VE-cadherin at cell junctions. Loss of TRAF7 abrogates Robo4's protective function, and Robo4-/- mice show increased vascular leakage and mortality in endotoxemia.","method":"Co-immunoprecipitation, deletion assays, gain- and loss-of-function studies, Robo4 knockout mouse endotoxemia model, permeability assays, VE-cadherin localization","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal binding assays, domain deletion mapping, loss-of-function in vivo (knockout mouse) with clear phenotypic readout, and gain-of-function rescue","pmids":["30510113"],"is_preprint":false},{"year":2021,"finding":"TRAF7 loss-of-function mutations disrupt either its catalytic E3 ligase activity or its interaction with RAS GTPases. TRAF7 acts as a proteostatic regulator of RAS-related small GTPases; TRAF7 loss in meningeal cells alters actin dynamics and promotes anchorage-independent growth by inducing CDC42 and RAS signaling. KLF4 loss of function disrupts a negative feedback loop (TRAF7-loss-driven RAS/MAPK pathway activates KLF4-dependent transcription of the Semaphorin pathway) and enhances TRAF7 mutant-mediated cell transformation.","method":"TRAF7 ubiquitinome and proteome analysis, interactome mapping, in vitro meningioma model from primary meningeal cells, genetic epistasis, actin dynamics assays, anchorage-independent growth assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods: ubiquitinome, proteome, interactome, functional cell transformation assays, epistasis in primary cells","pmids":["34215617"],"is_preprint":false},{"year":2021,"finding":"TRAF7 directly interacted with MEKK3 in neuronal/glial cells. Brain-specific TRAF7 deletion ameliorated neuronal death and neuroinflammation after TBI. MEKK3 overexpression abrogated the protective effects of TRAF7 knockout, establishing TRAF7 upstream of MEKK3 in NF-κB and MAPK signaling in brain.","method":"Brain-specific conditional knockout mice, Co-immunoprecipitation of TRAF7-MEKK3, MEKK3 overexpression rescue, primary cortical neuron/glial OGD/R model, cytokine measurement, NF-κB/MAPK pathway analysis","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP interaction, conditional knockout mouse model, epistasis via MEKK3 overexpression rescue, single lab","pmids":["34953447"],"is_preprint":false},{"year":2021,"finding":"TRAF7 promotes ubiquitin-proteasome-mediated degradation of p53 at K48 site in hepatocellular carcinoma cells. Physical interaction between TRAF7 and p53 was identified. TRAF7's pro-tumorigenic functions (inhibiting apoptosis, promoting proliferation/invasion) depended on p53 in rescue assays.","method":"Co-immunoprecipitation, ubiquitination assay specifying K48-linkage, rescue assays with p53, overexpression/knockdown with cell phenotype assays","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, K48-specific ubiquitination assay, and rescue experiments, single lab","pmids":["34775479"],"is_preprint":false},{"year":2023,"finding":"TRAF7 interacts with TBK1 and promotes K48-linked polyubiquitination and proteasomal degradation of TBK1 through its RING domain, impairing IRF3 activation and IFN-β production. The conserved cysteine at position 131 of TRAF7 is necessary for this function. TRAF7 knockout facilitated IRF3 activation and increased antiviral gene transcription.","method":"Co-immunoprecipitation, K48-specific ubiquitination assay, TRAF7 RING domain mutagenesis (C131 mutation), TRAF7 knockout cells, IRF3 activation assays, IFN-β reporter assay","journal":"Virologica Sinica","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — RING domain mutagenesis, K48 linkage-specific ubiquitination assay, knockout phenotype, and Co-IP in one focused study","pmids":["37086853"],"is_preprint":false},{"year":2023,"finding":"Targeted deletion of TRAF7 in mice is embryonic lethal due to impaired endothelium integrity, similar to Mekk3-, Mek5- or Erk5-deficient mice, with significantly lower expression of KLF2 downstream of MEKK3-MEK5-ERK5. TRAF7 associates with SCRIB (planar cell polarity protein) via its N-terminal region, while MEKK3 associates with the C-terminal WD40 domain. SCRIB and TRAF7 together mediate fluid shear stress-induced ERK5 phosphorylation in endothelial cells.","method":"Conditional knockout mouse (embryonic and endothelial-specific), Co-immunoprecipitation domain mapping of TRAF7-SCRIB and TRAF7-MEKK3, shear stress assays in cultured endothelial cells, ERK5/KLF2 Western blotting","journal":"iScience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — knockout mouse with clear phenotype, domain-specific interaction mapping, and functional shear stress assays with multiple signaling readouts","pmids":["37583551"],"is_preprint":false},{"year":2023,"finding":"TRAF7 mutants (associated with meningioma/congenital heart defects) operate in a dominant-negative manner by heterodimerizing with wild-type TRAF7 protein. Somatic and inherited TRAF7 mutations disrupt TRAF7-IFT57 interactions, leading to cilia degradation. TRAF7 knockdown in Xenopus and zebrafish caused cardiac, craniofacial, and ciliary defects. TRAF7-mutant meningioma primary cultures lack cilia.","method":"Heterodimerization assay (dominant-negative mechanism), Co-IP of TRAF7-IFT57, primary culture ciliogenesis assay, TRAF7 morpholino knockdown in Xenopus and zebrafish","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods: heterodimerization, Co-IP interaction with IFT57, primary culture cilia assay, and in vivo vertebrate model knockdown","pmids":["37043537"],"is_preprint":false},{"year":2024,"finding":"TRAF7 is an E3 ligase that forms a complex with E2 enzymes UBE2G1 and/or UBE2T to promote K48-linked polyubiquitination and proteasomal degradation of the circadian transcription factor DBP. TRAF7 knockout in NIH3T3 cells impairs time-of-day-dependent regulation of DBP levels, and TRAF7 overexpression shortens the circadian period.","method":"Proteomic analysis of DBP-interacting proteins, dominant-negative E2 screen (19 variants), Co-IP of TRAF7-UBE2G1/UBE2T-DBP complex, K48-specific ubiquitination assay, TRAF7 knockout in NIH3T3, circadian period assay","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — proteomic interactome, E2 enzyme screen, K48 ubiquitination assay, knockout with circadian phenotype — multiple orthogonal methods in one study","pmids":["39379486"],"is_preprint":false},{"year":2024,"finding":"TRAF7 interacts with KLF4 and promotes its ubiquitin-mediated degradation. H2S S-sulfhydrates TRAF7 at Cys327, which weakens the TRAF7-KLF4 interaction and reduces ubiquitination of KLF4, thereby stabilizing KLF4 and upregulating VE-cadherin to protect endothelial barrier integrity. A TRAF7-Cys327 mutant mimicking S-sulfhydration recapitulated these protective effects.","method":"S-sulfhydration assay, Co-immunoprecipitation, ubiquitination assay, TRAF7-Cys327 mutagenesis, VE-cadherin expression/localization, endothelial permeability assay","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — site-specific mutagenesis (Cys327), S-sulfhydration assay, Co-IP, ubiquitination assay, and functional barrier assay in one focused study","pmids":["38479633"],"is_preprint":false},{"year":2024,"finding":"The C. trachomatis effector Tri1 specifically interacts with TRAF7 during infection, recruits TRAF7 to the Chlamydia inclusion, and displaces native TRAF7 binding partners MEKK2 and MEKK3. The Tri1 coiled-coil domain is necessary for interaction with the TRAF7 WD40 domain. These findings confirm MEKK2 and MEKK3 as endogenous TRAF7 WD40-binding partners.","method":"Co-affinity purification, immunofluorescence confocal imaging, proteomics, domain deletion assays, infection-based interaction studies","journal":"Microbiology spectrum","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-affinity purification with proteomics, domain mapping, and imaging in infection context; single lab","pmids":["38814079"],"is_preprint":false},{"year":2025,"finding":"TRAF7 interacts with SOX12 protein and promotes K48-linked ubiquitination-mediated proteasomal degradation of SOX12 in esophageal squamous cell carcinoma cells. TRAF7's inhibitory effects on tumor cell proliferation and migration partly depended on SOX12, as shown by rescue experiments.","method":"Co-immunoprecipitation, K48-specific ubiquitination assay, rescue assay with SOX12 overexpression, cell proliferation and migration assays","journal":"Biochemistry and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP, ubiquitination assay, and rescue experiment from a single lab with limited orthogonal validation","pmids":["40623321"],"is_preprint":false},{"year":2018,"finding":"In vitro analyses of de novo germline TRAF7 missense mutations found in patients with developmental delay and congenital anomalies showed reduced ERK1/2 phosphorylation, indicating that TRAF7 promotes ERK1/2 signaling under normal conditions.","method":"In vitro expression of patient-derived TRAF7 mutants, Western blot for ERK1/2 phosphorylation","journal":"American journal of human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single in vitro functional assay (phospho-Western), single lab, limited mechanistic follow-up","pmids":["29961569"],"is_preprint":false}],"current_model":"TRAF7 is a RING finger–containing E3 ubiquitin ligase that uses its RING domain to catalyze predominantly K48-linked polyubiquitination (targeting substrates including TBK1, p53, KLF4, HOXA5, SOX12, and DBP for proteasomal degradation) and K29-linked ubiquitination of NEMO/p65 leading to lysosomal degradation, while its WD40 domain mediates protein–protein interactions with MEKK2, MEKK3, SCRIB, Robo4, and IFT57; through these interactions TRAF7 positions upstream in the shear stress–responsive MEKK3–MEK5–ERK5–KLF2 endothelial signaling axis, negatively regulates NF-κB by degrading NEMO and p65, represses c-Myb by cytoplasmic sequestration via sumoylation, promotes AP1/CHOP activation via MEKK3, cooperates with CYLD in a TLR2 feedback loop, regulates ciliogenesis via IFT57, controls circadian period via DBP turnover, and is a direct transcriptional target of MyoD1 that couples NF-κB activity to myogenesis; somatic mutations disrupting TRAF7 catalytic activity or its interaction with RAS GTPases activate CDC42/RAS signaling and drive meningioma and other tumor development, while germline dominant-negative mutations cause a developmental syndrome via heterodimerization with wild-type protein and loss of cilia."},"narrative":{"mechanistic_narrative":"TRAF7 is a RING finger–containing E3 ubiquitin ligase that integrates protein-degradation control with scaffold-based signal transduction to regulate inflammatory signaling, endothelial homeostasis, and cellular growth [PMID:15001576, PMID:21518757]. Through its RING domain and a conserved catalytic cysteine, TRAF7 catalyzes ubiquitination of multiple substrates: it drives K48-linked polyubiquitination and proteasomal degradation of TBK1 (dampening IRF3/IFN-β antiviral responses) [PMID:37086853], of the circadian transcription factor DBP in concert with the E2 enzymes UBE2G1/UBE2T to set circadian period [PMID:39379486], and of tumor-suppressive or developmental transcription factors p53, KLF4, and SOX12 in cancer cells [PMID:31730901, PMID:34775479, PMID:40623321]; it also promotes K29-linked ubiquitination of NEMO and p65/RelA, routing them to lysosomal degradation to repress NF-κB [PMID:21518757, PMID:20948544]. Its seven WD40 repeats mediate protein interactions—most notably with the MAP3Ks MEKK2 and MEKK3 [PMID:15001576, PMID:38814079]—placing TRAF7 upstream in the fluid shear stress–responsive MEKK3–MEK5–ERK5–KLF2 endothelial axis together with SCRIB, where its loss is embryonic lethal from impaired endothelial integrity [PMID:37583551]. TRAF7 additionally supports endothelial barrier function via Robo4 and VE-cadherin stabilization [PMID:30510113, PMID:38479633] and negatively regulates c-Myb by promoting its sumoylation and cytoplasmic sequestration [PMID:16162816]. Somatic loss-of-function mutations that disrupt catalysis or RAS-GTPase interaction activate CDC42/RAS signaling and drive meningioma and other tumors [PMID:34215617], while dominant-negative germline mutations act through heterodimerization with wild-type protein and disrupt TRAF7–IFT57-dependent ciliogenesis, causing a developmental syndrome [PMID:37043537].","teleology":[{"year":2004,"claim":"Established TRAF7 as a domain-defined TRAF family member and linked it functionally to MAP3K signaling, answering what kind of protein it is and what pathway it engages.","evidence":"Co-IP, antisense depletion, domain mapping, and reporter assays showing MEKK3-dependent AP1/CHOP activation and apoptosis induction","pmids":["15001576"],"confidence":"High","gaps":["Did not establish ubiquitin ligase substrates","Apoptosis mechanism not resolved at the substrate level"]},{"year":2005,"claim":"Showed TRAF7 acts as a transcriptional repressor of c-Myb through stimulation of sumoylation and cytoplasmic sequestration, and confirmed intrinsic E3 ligase activity via self-ubiquitination.","evidence":"Co-IP/domain mapping, in vitro sumoylation assay with site mutants, reporter assays, and subcellular fractionation","pmids":["16162816"],"confidence":"High","gaps":["Mechanism by which TRAF7 stimulates sumoylation unclear","Physiological context of c-Myb regulation not defined"]},{"year":2005,"claim":"Placed TRAF7 in TLR2-driven innate signaling alongside TRAF6 with CYLD as a negative regulator, broadening its role beyond MEKK3.","evidence":"Overexpression/reporter epistasis for NF-κB and p38 with TLR2 ligand stimulation","pmids":["16230348"],"confidence":"Medium","gaps":["Reliance on overexpression rather than endogenous loss-of-function","Direct CYLD-TRAF7 deubiquitination not shown biochemically"]},{"year":2010,"claim":"Identified TRAF7 as a direct MyoD1 transcriptional target controlling NF-κB during myogenesis and identified NEMO as a TRAF7 interactor whose ubiquitylation depends on TRAF7.","evidence":"ChIP, siRNA depletion with differentiation assays, proteomic Co-IP screen, and ubiquitylation assays in myoblasts","pmids":["20948544"],"confidence":"High","gaps":["Ubiquitin linkage type on NEMO not specified here","Generality beyond muscle context unknown"]},{"year":2011,"claim":"Defined a mechanism for TRAF7-mediated NF-κB repression via K29-linked ubiquitination and lysosomal degradation of NEMO and p65.","evidence":"Reciprocal Co-IP, K29-linkage-specific ubiquitination, lysosomal inhibitor rescue, and transcriptomic analysis","pmids":["21518757"],"confidence":"High","gaps":["Atypical K29 linkage mechanism not structurally explained","In vivo relevance of lysosomal routing not tested"]},{"year":2017,"claim":"Linked tumor-associated WD40-domain mutations to gain of aberrant NF-κB activation, connecting genotype to a signaling output.","evidence":"WT vs mutant expression with p-NF-κB/L1CAM Westerns and IHC in adenomatoid tumors","pmids":["29148537"],"confidence":"Medium","gaps":["Single in vitro system","Mechanism connecting WD40 mutation to NF-κB activation not resolved"]},{"year":2018,"claim":"Indicated TRAF7 normally promotes ERK1/2 signaling, since germline syndrome mutations reduce ERK1/2 phosphorylation.","evidence":"In vitro expression of patient-derived mutants with phospho-ERK1/2 Western blot","pmids":["29961569"],"confidence":"Low","gaps":["Single phospho-Western readout without mechanistic follow-up","No endogenous or in vivo confirmation","Relationship to ERK5 axis unclear"]},{"year":2019,"claim":"Extended TRAF7 substrate range to KLF4 in cancer, coupling its ligase activity to pro-metastatic motility.","evidence":"Co-IP, ubiquitination assay, KLF4 rescue, and migration/invasion assays in vitro and in vivo","pmids":["31730901"],"confidence":"Medium","gaps":["Ubiquitin linkage on KLF4 not specified in this study","Single tumor type"]},{"year":2019,"claim":"Showed TRAF7 is required for Robo4-mediated protection of endothelial barrier integrity, establishing a vascular function.","evidence":"Reciprocal binding, deletion mapping, gain/loss-of-function, and Robo4 knockout mouse endotoxemia model","pmids":["30510113"],"confidence":"High","gaps":["Whether TRAF7 ligase activity is required downstream of Robo4 not resolved","Direct effector of VE-cadherin stabilization not identified"]},{"year":2021,"claim":"Defined TRAF7 as a proteostatic regulator of RAS-related GTPases whose loss drives CDC42/RAS signaling and meningeal cell transformation, mechanistically explaining tumorigenic mutations.","evidence":"Ubiquitinome/proteome/interactome analysis, primary meningeal cell transformation model, and genetic epistasis with KLF4","pmids":["34215617"],"confidence":"High","gaps":["Direct GTPase ubiquitination substrate(s) not fully enumerated","How mutations selectively impair RAS interaction not structurally defined"]},{"year":2021,"claim":"Confirmed TRAF7 acts upstream of MEKK3 in NF-κB/MAPK signaling in brain, with loss conferring neuroprotection after injury.","evidence":"Brain-specific conditional knockout, Co-IP, MEKK3 overexpression rescue, and OGD/R neuron-glia models","pmids":["34953447"],"confidence":"Medium","gaps":["Single lab","Role of ligase activity vs scaffold function in this context unclear"]},{"year":2021,"claim":"Identified p53 as a TRAF7 K48-ubiquitination substrate, explaining a route to its pro-tumorigenic activity in HCC.","evidence":"Co-IP, K48-specific ubiquitination assay, and p53-dependent rescue with phenotype assays","pmids":["34775479"],"confidence":"Medium","gaps":["Single tumor system","Relationship to KLF4 degradation in same cells not integrated"]},{"year":2023,"claim":"Demonstrated RING- and C131-dependent K48 ubiquitination of TBK1 by TRAF7, defining a negative regulatory node in antiviral IFN signaling.","evidence":"Co-IP, K48-specific ubiquitination, RING/C131 mutagenesis, knockout cells, and IRF3/IFN-β assays","pmids":["37086853"],"confidence":"High","gaps":["In vivo antiviral relevance not tested","Regulation of TRAF7 activity during infection unknown"]},{"year":2023,"claim":"Established TRAF7 as essential for endothelial integrity through the shear stress–responsive MEKK3–MEK5–ERK5–KLF2 axis, mapping SCRIB and MEKK3 to distinct TRAF7 regions.","evidence":"Conditional knockout mice with embryonic lethality, domain-specific Co-IP mapping, and shear stress assays with ERK5/KLF2 readouts","pmids":["37583551"],"confidence":"High","gaps":["Whether ubiquitin ligase activity is required for ERK5 activation unresolved","Order of SCRIB/MEKK3 assembly on TRAF7 not defined"]},{"year":2023,"claim":"Explained the genetic mechanism of TRAF7-associated developmental syndrome and tumors through dominant-negative heterodimerization and disrupted IFT57-dependent ciliogenesis.","evidence":"Heterodimerization assay, TRAF7-IFT57 Co-IP, primary culture cilia assay, and morpholino knockdown in Xenopus and zebrafish","pmids":["37043537"],"confidence":"High","gaps":["Mechanism connecting IFT57 binding to cilia maintenance not detailed","Whether ciliary defects underlie all syndrome features unknown"]},{"year":2024,"claim":"Identified TRAF7 as the E3 ligase, with UBE2G1/UBE2T, that controls DBP turnover and circadian period, extending its substrate repertoire to clock regulation.","evidence":"Proteomic interactome, E2 dominant-negative screen, Co-IP of the TRAF7-E2-DBP complex, K48 ubiquitination, and circadian period assay in knockout cells","pmids":["39379486"],"confidence":"High","gaps":["How TRAF7 activity is gated by time of day unknown","Physiological circadian phenotype in vivo not tested"]},{"year":2024,"claim":"Showed that H2S-driven S-sulfhydration of TRAF7 at Cys327 inhibits KLF4 ubiquitination, defining a redox switch that stabilizes the endothelial barrier.","evidence":"S-sulfhydration assay, Co-IP, ubiquitination assay, Cys327 mutagenesis, and endothelial permeability/VE-cadherin assays","pmids":["38479633"],"confidence":"High","gaps":["Endogenous source/dynamics of H2S modification in vivo not established","Interplay with C131 catalytic cysteine unclear"]},{"year":2024,"claim":"Confirmed MEKK2 and MEKK3 as endogenous WD40-binding partners of TRAF7 by showing a pathogen effector displaces them, validating the scaffold interface.","evidence":"Co-affinity purification, proteomics, confocal imaging, and domain deletion mapping in Chlamydia infection","pmids":["38814079"],"confidence":"Medium","gaps":["Functional consequence of MEKK displacement on host signaling not quantified","Single pathogen system"]},{"year":2025,"claim":"Added SOX12 as a K48-ubiquitination substrate of TRAF7 with tumor-suppressive consequences in esophageal squamous cell carcinoma.","evidence":"Co-IP, K48-specific ubiquitination, and SOX12-dependent rescue with proliferation/migration assays","pmids":["40623321"],"confidence":"Medium","gaps":["Single lab with limited orthogonal validation","Tissue-specificity of substrate choice unexplained"]},{"year":null,"claim":"It remains unresolved how TRAF7 selects among its diverse substrates and switches between scaffold (MEKK2/3-ERK5) and catalytic (degradative) modes across tissues.","evidence":"No timeline study integrates the full substrate set with a unifying recruitment or regulatory logic","pmids":[],"confidence":"Low","gaps":["No structural model of substrate recognition by the WD40/RING architecture","Regulation of ubiquitin linkage choice (K48 vs K29) not mechanistically explained","Tissue-specific determinants of substrate preference unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[1,3,11,14]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,6,10,11,14,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,8,12]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,12]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,9,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,3,11]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,11,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,13]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,13]}],"complexes":[],"partners":["MAP3K3","MAP3K2","IKBKG","RELA","SCRIB","ROBO4","IFT57","TBK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6Q0C0","full_name":"E3 ubiquitin-protein ligase TRAF7","aliases":["RING finger and WD repeat-containing protein 1","RING finger protein 119","RING-type E3 ubiquitin transferase TRAF7","TNF receptor-associated factor 7"],"length_aa":670,"mass_kda":74.6,"function":"E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis (PubMed:15001576, PubMed:37086853). Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators (PubMed:14743216). Negatively regulates MYB transcriptional activity by sequestering it to the cytosol via SUMOylation (By similarity). Plays a role in the phosphorylation of MAPK1 and/or MAPK3, probably via its interaction with MAP3K3. Negatively regulates RLR-mediated innate immunity by promoting 'Lys-48'-linked ubiquitination of TBK1 through its RING domain to inhibit the cellular antiviral response (PubMed:37086853). Promotes 'Lys-29'-linked polyubiquitination of NEMO/IKBKG and RELA leading to targeting these two proteins to lysosomal degradative pathways, reducing the transcriptional activity of NF-kappa-B (PubMed:21518757)","subcellular_location":"Cytoplasmic vesicle; Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q6Q0C0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRAF7","classification":"Not Classified","n_dependent_lines":70,"n_total_lines":1208,"dependency_fraction":0.057947019867549666},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SF3B3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TRAF7","total_profiled":1310},"omim":[{"mim_id":"618164","title":"CARDIAC, FACIAL, AND DIGITAL ANOMALIES WITH DEVELOPMENTAL DELAY; CAFDADD","url":"https://www.omim.org/entry/618164"},{"mim_id":"606692","title":"TNF RECEPTOR-ASSOCIATED FACTOR 7; TRAF7","url":"https://www.omim.org/entry/606692"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRAF7"},"hgnc":{"alias_symbol":["RNF119","DKFZp586I021","MGC7807"],"prev_symbol":["RFWD1"]},"alphafold":{"accession":"Q6Q0C0","domains":[{"cath_id":"3.30.40.10","chopping":"121-229","consensus_level":"high","plddt":87.7431,"start":121,"end":229},{"cath_id":"2.130.10.10","chopping":"398-645","consensus_level":"high","plddt":95.7089,"start":398,"end":645},{"cath_id":"4.10.280","chopping":"255-332","consensus_level":"medium","plddt":90.744,"start":255,"end":332}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6Q0C0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6Q0C0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6Q0C0-F1-predicted_aligned_error_v6.png","plddt_mean":79.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRAF7","jax_strain_url":"https://www.jax.org/strain/search?query=TRAF7"},"sequence":{"accession":"Q6Q0C0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6Q0C0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6Q0C0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6Q0C0"}},"corpus_meta":[{"pmid":"23348505","id":"PMC_23348505","title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23348505","citation_count":721,"is_preprint":false},{"pmid":"23404370","id":"PMC_23404370","title":"Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.","date":"2013","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/23404370","citation_count":201,"is_preprint":false},{"pmid":"16230348","id":"PMC_16230348","title":"The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16230348","citation_count":171,"is_preprint":false},{"pmid":"15001576","id":"PMC_15001576","title":"TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15001576","citation_count":147,"is_preprint":false},{"pmid":"22105767","id":"PMC_22105767","title":"The seventh ring: exploring TRAF7 functions.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22105767","citation_count":90,"is_preprint":false},{"pmid":"29148537","id":"PMC_29148537","title":"Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/29148537","citation_count":79,"is_preprint":false},{"pmid":"30171198","id":"PMC_30171198","title":"Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.","date":"2018","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/30171198","citation_count":77,"is_preprint":false},{"pmid":"21518757","id":"PMC_21518757","title":"TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21518757","citation_count":76,"is_preprint":false},{"pmid":"27808423","id":"PMC_27808423","title":"The Emerging Role of TRAF7 in Tumor Development.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27808423","citation_count":71,"is_preprint":false},{"pmid":"28019650","id":"PMC_28019650","title":"Genomic analysis reveals frequent TRAF7 mutations in intraneural perineuriomas.","date":"2017","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28019650","citation_count":59,"is_preprint":false},{"pmid":"16162816","id":"PMC_16162816","title":"TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16162816","citation_count":51,"is_preprint":false},{"pmid":"29961569","id":"PMC_29961569","title":"De Novo Missense Variants in TRAF7 Cause Developmental Delay, Congenital Anomalies, and Dysmorphic Features.","date":"2018","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29961569","citation_count":47,"is_preprint":false},{"pmid":"25318608","id":"PMC_25318608","title":"MicroRNA-126 attenuates palmitate-induced apoptosis by targeting TRAF7 in HUVECs.","date":"2014","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25318608","citation_count":36,"is_preprint":false},{"pmid":"31730901","id":"PMC_31730901","title":"TRAF7 enhances ubiquitin-degradation of KLF4 to promote hepatocellular carcinoma progression.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31730901","citation_count":33,"is_preprint":false},{"pmid":"32376980","id":"PMC_32376980","title":"Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7.","date":"2020","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32376980","citation_count":33,"is_preprint":false},{"pmid":"31470906","id":"PMC_31470906","title":"Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/31470906","citation_count":30,"is_preprint":false},{"pmid":"34215617","id":"PMC_34215617","title":"Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34215617","citation_count":28,"is_preprint":false},{"pmid":"30510113","id":"PMC_30510113","title":"The Robo4-TRAF7 complex suppresses endothelial hyperpermeability in inflammation.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/30510113","citation_count":27,"is_preprint":false},{"pmid":"20948544","id":"PMC_20948544","title":"Traf7, a MyoD1 transcriptional target, regulates nuclear factor-κB activity during myogenesis.","date":"2010","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/20948544","citation_count":24,"is_preprint":false},{"pmid":"29940130","id":"PMC_29940130","title":"MicroRNA-126 attenuates cell apoptosis by targeting TRAF7 in acute myeloid leukemia cells.","date":"2018","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/29940130","citation_count":22,"is_preprint":false},{"pmid":"33667423","id":"PMC_33667423","title":"TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma.","date":"2021","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33667423","citation_count":21,"is_preprint":false},{"pmid":"34775479","id":"PMC_34775479","title":"TRAF7 contributes to tumor progression by promoting ubiquitin-proteasome mediated degradation of P53 in hepatocellular carcinoma.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34775479","citation_count":20,"is_preprint":false},{"pmid":"37043537","id":"PMC_37043537","title":"Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37043537","citation_count":15,"is_preprint":false},{"pmid":"37583551","id":"PMC_37583551","title":"TRAF7 is an essential regulator of blood vessel integrity during mouse embryonic and neonatal development.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37583551","citation_count":14,"is_preprint":false},{"pmid":"37086853","id":"PMC_37086853","title":"TRAF7 negatively regulates the RLR signaling pathway by facilitating the K48-linked ubiquitination of TBK1.","date":"2023","source":"Virologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37086853","citation_count":13,"is_preprint":false},{"pmid":"21872663","id":"PMC_21872663","title":"The first homolog of a TRAF7 (TNF receptor-associated factor 7) gene in a mollusk, Crassostrea hongkongensis.","date":"2011","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21872663","citation_count":13,"is_preprint":false},{"pmid":"38927638","id":"PMC_38927638","title":"Expression of Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) Candidate Genes EDA2R, PCDH9, and TRAF7 in Normal Human Kidney Development and CAKUT.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38927638","citation_count":12,"is_preprint":false},{"pmid":"37003349","id":"PMC_37003349","title":"TRAF7 inhibits glycolysis to potentiate growth inhibition and apoptosis of myeloid leukemia cells via regulating the KLF2-PFKFB3 axis.","date":"2023","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/37003349","citation_count":11,"is_preprint":false},{"pmid":"33677813","id":"PMC_33677813","title":"Long non-coding RNA NEAT1 regulates endothelial functions in subclinical hypothyroidism through miR-126/TRAF7 pathway.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/33677813","citation_count":10,"is_preprint":false},{"pmid":"38479633","id":"PMC_38479633","title":"Hydrogen sulfide improves endothelial barrier function by modulating the ubiquitination degradation of KLF4 through TRAF7 S-sulfhydration in diabetic aorta.","date":"2024","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38479633","citation_count":10,"is_preprint":false},{"pmid":"37845209","id":"PMC_37845209","title":"TRAF7-targeted HOXA5 acts as a tumor suppressor in prostate cancer progression and stemness via transcriptionally activating SPRY2 and regulating MEK/ERK signaling.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37845209","citation_count":9,"is_preprint":false},{"pmid":"34513876","id":"PMC_34513876","title":"Case Report: Blepharophimosis and Ptosis as Leading Dysmorphic Features of Rare Congenital Malformation Syndrome With Developmental Delay - New Cases With TRAF7 Variants.","date":"2021","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34513876","citation_count":8,"is_preprint":false},{"pmid":"40181456","id":"PMC_40181456","title":"TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence.","date":"2025","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/40181456","citation_count":7,"is_preprint":false},{"pmid":"40868928","id":"PMC_40868928","title":"Review of the Role of TRAF7 in Brain Endothelial Integrity and Cerebrovascular Aging.","date":"2025","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40868928","citation_count":7,"is_preprint":false},{"pmid":"36395468","id":"PMC_36395468","title":"TRAF7-mutated Fibromyxoid Spindle Cell Tumors Are Associated With an Aggressive Clinical Course and Harbor an Undifferentiated Sarcoma Methylation Signature: A Molecular and Clinicopathologic Study of 3 Cases.","date":"2022","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36395468","citation_count":7,"is_preprint":false},{"pmid":"34953447","id":"PMC_34953447","title":"Brain-specific TRAF7 deletion ameliorates traumatic brain injury by suppressing MEKK3-regulated glial inflammation and neuronal death.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34953447","citation_count":6,"is_preprint":false},{"pmid":"36463437","id":"PMC_36463437","title":"Propofol inhibits cell apoptosis and inflammatory response in ox-LDL-induced human umbilical vein endothelial cells through the modulation of the circ_0003645/miR-149-3p/TRAF7 axis.","date":"2023","source":"Clinical hemorheology and microcirculation","url":"https://pubmed.ncbi.nlm.nih.gov/36463437","citation_count":5,"is_preprint":false},{"pmid":"34247275","id":"PMC_34247275","title":"Multi-suture craniosynostosis in c.1570C>T (p.Arg524Trp) mutated TRAF7: a case report.","date":"2021","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/34247275","citation_count":5,"is_preprint":false},{"pmid":"40650197","id":"PMC_40650197","title":"Spatial and Temporal Expression Patterns of EDA2R, PCDH9, and TRAF7 in Yotari (Dab1) Mice: Implicationsfor Understanding CAKUT Pathogenesis.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40650197","citation_count":4,"is_preprint":false},{"pmid":"39379486","id":"PMC_39379486","title":"TRAF7 determines circadian period through ubiquitination and degradation of DBP.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39379486","citation_count":3,"is_preprint":false},{"pmid":"38569228","id":"PMC_38569228","title":"Expanding the Phenotypic Spectrum of TRAF7-Related Cardiac, Facial, and Digital Anomalies With Developmental Delay: Report of 11 New Cases and Literature Review.","date":"2024","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38569228","citation_count":3,"is_preprint":false},{"pmid":"35733823","id":"PMC_35733823","title":"TRAF7 somatic mosaicism in a patient with bilateral optic nerve sheath meningiomas: illustrative case.","date":"2022","source":"Journal of neurosurgery. Case lessons","url":"https://pubmed.ncbi.nlm.nih.gov/35733823","citation_count":3,"is_preprint":false},{"pmid":"41372821","id":"PMC_41372821","title":"TRAF7 in signaling and disease: emerging mechanisms and clinical implications.","date":"2025","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/41372821","citation_count":2,"is_preprint":false},{"pmid":"41229068","id":"PMC_41229068","title":"TRAF7-Mutated Myxoid and Spindle Cell Mesenchymal Tumor Occurring in a Pediatric Patient in the Post-Transplant Setting: Expanding the Spectrum of TRAF7-Mutated Tumors.","date":"2025","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41229068","citation_count":2,"is_preprint":false},{"pmid":"38814079","id":"PMC_38814079","title":"The Chlamydia trachomatis Inc Tri1 interacts with TRAF7 to displace native TRAF7 interacting partners.","date":"2024","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/38814079","citation_count":1,"is_preprint":false},{"pmid":"39466916","id":"PMC_39466916","title":"cba-miR-222-3p involved in photoperiod-induced apoptosis in testes of striped hamsters by targeting TRAF7.","date":"2024","source":"Integrative zoology","url":"https://pubmed.ncbi.nlm.nih.gov/39466916","citation_count":1,"is_preprint":false},{"pmid":"40623321","id":"PMC_40623321","title":"TRAF7 inhibits proliferation and migration of esophageal squamous cell carcinoma by ubiquitination-mediated degradation of SOX12.","date":"2025","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/40623321","citation_count":0,"is_preprint":false},{"pmid":"38464023","id":"PMC_38464023","title":"The Chlamydia trachomatis Inc Tri1 interacts with TRAF7 to displace native TRAF7 interacting partners.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38464023","citation_count":0,"is_preprint":false},{"pmid":"40761367","id":"PMC_40761367","title":"Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights.","date":"2025","source":"SAGE open medical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/40761367","citation_count":0,"is_preprint":false},{"pmid":"41811066","id":"PMC_41811066","title":"TRAF7-Mutated Fibromyxoid Spindle Cell Tumor of Bone: An Osseous Case Expanding the Spectrum of TRAF7-Mutated Tumors With Over 20 Years Clinical Follow-Up.","date":"2026","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41811066","citation_count":0,"is_preprint":false},{"pmid":"41608005","id":"PMC_41608005","title":"Primary TRAF7-Mutated Myxoid Mesenchymal Tumor With Predominant Epithelioid Morphology: Expanding the Morphologic Spectrum of TRAF7-Mutated Myxoid Mesenchymal Tumors.","date":"2025","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/41608005","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.03.25326857","title":"ARID1A expression and genomic alterations as predictive biomarkers for metachronous colorectal polyp risk stratification","date":"2025-05-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.03.25326857","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27729,"output_tokens":5683,"usd":0.084216,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14051,"output_tokens":5617,"usd":0.10534,"stage2_stop_reason":"end_turn"},"total_usd":0.189556,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"TRAF7 was identified as a novel TRAF family member containing a RING finger domain, zinc finger domain, and seven WD40 repeats. It specifically interacted with MEKK3 and potentiated MEKK3-mediated AP1 and CHOP activation; depletion by antisense RNA inhibited this activation. Overexpression induced caspase-dependent apoptosis. Domain mapping showed TRAF7 uses distinct domains for MEKK3 signaling versus apoptosis induction.\",\n      \"method\": \"Co-immunoprecipitation, antisense RNA depletion, overexpression with reporter assays, domain mapping, caspase activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction shown, antisense knockdown with defined phenotype, domain mapping, and replicated across multiple orthogonal methods in a single focused study\",\n      \"pmids\": [\"15001576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TRAF7 binds to the DNA-binding domain of c-Myb via its WD40 repeats and stimulates sumoylation of c-Myb at Lys-523 and Lys-499 (same sites as PIASy-induced sumoylation). TRAF7 has E3 ubiquitin ligase activity for self-ubiquitination. TRAF7 inhibited c-Myb-induced transactivation dependent on sumoylation sites. Overexpressed TRAF7 localizes to the cytoplasm and sequesters c-Myb and SUMO1 there, thereby negatively regulating c-Myb activity.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, sumoylation assay, transcriptional reporter assay, immunofluorescence/subcellular fractionation, mutagenesis of sumoylation sites\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro sumoylation assay with mutagenesis, Co-IP domain mapping, and functional transcriptional assay with sumoylation-site mutant controls\",\n      \"pmids\": [\"16162816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Activation of TLR2 signaling induces activation of IKKs-IκBα and MKK3/6-p38 pathways not only through TRAF6 but also through TRAF7. CYLD tumor suppressor acts as a negative regulator of both TRAF6 and TRAF7, likely via a deubiquitination-dependent mechanism, forming an autoregulatory feedback loop controlling NF-κB-dependent inflammatory responses.\",\n      \"method\": \"Overexpression, reporter assays for NF-κB and p38 activation, TLR2 ligand stimulation (PGN, MALP-2, Pam3CSK4), cytokine measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis via overexpression/reporter assays, single lab, two orthogonal readouts (IKK and p38 pathways)\",\n      \"pmids\": [\"16230348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TRAF7 physically associates with NEMO (IKKγ) and p65/RelA. TRAF7 promotes Lys-29-linked polyubiquitination of both NEMO and p65, leading to their lysosomal degradation and repression of NF-κB transcriptional activity. TRAF7 also influences p65 nuclear distribution and promotes cell death.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays with K29-linkage-specific analysis, lysosomal inhibitor experiments, microarray expression analysis, cell death assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP, linkage-specific ubiquitination assay, lysosomal degradation rescue experiment, and transcriptomic validation in one study\",\n      \"pmids\": [\"21518757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Traf7 is a direct transcriptional target of MyoD1 in muscle cells. Traf7 depletion accelerates myogenesis partly through downregulation of NF-κB activity. NEMO was identified as a Traf7-interacting protein by proteomic screen, and ubiquitylation of NEMO is regulated exclusively by Traf7 activity in myoblasts, coupling MyoD1 function to NF-κB activity.\",\n      \"method\": \"ChIP (MyoD1 binding to Traf7 promoter), siRNA depletion with myogenic differentiation assays, proteomic/co-IP screen identifying NEMO, ubiquitylation assays in myoblasts\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct target identification, Co-IP interactome, ubiquitylation assay, and loss-of-function with defined cellular phenotype in one study\",\n      \"pmids\": [\"20948544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Expression of mutant (but not wild-type) TRAF7 in vitro led to increased phosphorylation of NF-κB and increased expression of L1CAM, a marker of NF-κB pathway activation, demonstrating that adenomatoid tumor-associated TRAF7 WD40 domain mutations drive aberrant NF-κB pathway activation.\",\n      \"method\": \"In vitro expression of wild-type vs. mutant TRAF7, Western blot for p-NF-κB and L1CAM, immunohistochemistry\",\n      \"journal\": \"Modern pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, functional in vitro assay comparing WT vs. mutant, with IHC validation but limited mechanistic depth\",\n      \"pmids\": [\"29148537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRAF7 interacts with KLF4 protein via its N-terminus and promotes ubiquitin-mediated proteasomal degradation of KLF4, thereby promoting HCC cell migration and invasion. Restoration of KLF4 abrogated TRAF7-induced cell motility.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, KLF4 overexpression rescue, migration/invasion assays in vitro and in vivo\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, and rescue experiment with defined cellular phenotype, single lab\",\n      \"pmids\": [\"31730901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Robo4 binds to TRAF7 through interaction with the C-terminus of Robo4 in endothelial cells. TRAF7 is required for Robo4-mediated suppression of TNFα-induced vascular hyperpermeability and stabilization of VE-cadherin at cell junctions. Loss of TRAF7 abrogates Robo4's protective function, and Robo4-/- mice show increased vascular leakage and mortality in endotoxemia.\",\n      \"method\": \"Co-immunoprecipitation, deletion assays, gain- and loss-of-function studies, Robo4 knockout mouse endotoxemia model, permeability assays, VE-cadherin localization\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding assays, domain deletion mapping, loss-of-function in vivo (knockout mouse) with clear phenotypic readout, and gain-of-function rescue\",\n      \"pmids\": [\"30510113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAF7 loss-of-function mutations disrupt either its catalytic E3 ligase activity or its interaction with RAS GTPases. TRAF7 acts as a proteostatic regulator of RAS-related small GTPases; TRAF7 loss in meningeal cells alters actin dynamics and promotes anchorage-independent growth by inducing CDC42 and RAS signaling. KLF4 loss of function disrupts a negative feedback loop (TRAF7-loss-driven RAS/MAPK pathway activates KLF4-dependent transcription of the Semaphorin pathway) and enhances TRAF7 mutant-mediated cell transformation.\",\n      \"method\": \"TRAF7 ubiquitinome and proteome analysis, interactome mapping, in vitro meningioma model from primary meningeal cells, genetic epistasis, actin dynamics assays, anchorage-independent growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods: ubiquitinome, proteome, interactome, functional cell transformation assays, epistasis in primary cells\",\n      \"pmids\": [\"34215617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAF7 directly interacted with MEKK3 in neuronal/glial cells. Brain-specific TRAF7 deletion ameliorated neuronal death and neuroinflammation after TBI. MEKK3 overexpression abrogated the protective effects of TRAF7 knockout, establishing TRAF7 upstream of MEKK3 in NF-κB and MAPK signaling in brain.\",\n      \"method\": \"Brain-specific conditional knockout mice, Co-immunoprecipitation of TRAF7-MEKK3, MEKK3 overexpression rescue, primary cortical neuron/glial OGD/R model, cytokine measurement, NF-κB/MAPK pathway analysis\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP interaction, conditional knockout mouse model, epistasis via MEKK3 overexpression rescue, single lab\",\n      \"pmids\": [\"34953447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAF7 promotes ubiquitin-proteasome-mediated degradation of p53 at K48 site in hepatocellular carcinoma cells. Physical interaction between TRAF7 and p53 was identified. TRAF7's pro-tumorigenic functions (inhibiting apoptosis, promoting proliferation/invasion) depended on p53 in rescue assays.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay specifying K48-linkage, rescue assays with p53, overexpression/knockdown with cell phenotype assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, K48-specific ubiquitination assay, and rescue experiments, single lab\",\n      \"pmids\": [\"34775479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRAF7 interacts with TBK1 and promotes K48-linked polyubiquitination and proteasomal degradation of TBK1 through its RING domain, impairing IRF3 activation and IFN-β production. The conserved cysteine at position 131 of TRAF7 is necessary for this function. TRAF7 knockout facilitated IRF3 activation and increased antiviral gene transcription.\",\n      \"method\": \"Co-immunoprecipitation, K48-specific ubiquitination assay, TRAF7 RING domain mutagenesis (C131 mutation), TRAF7 knockout cells, IRF3 activation assays, IFN-β reporter assay\",\n      \"journal\": \"Virologica Sinica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — RING domain mutagenesis, K48 linkage-specific ubiquitination assay, knockout phenotype, and Co-IP in one focused study\",\n      \"pmids\": [\"37086853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Targeted deletion of TRAF7 in mice is embryonic lethal due to impaired endothelium integrity, similar to Mekk3-, Mek5- or Erk5-deficient mice, with significantly lower expression of KLF2 downstream of MEKK3-MEK5-ERK5. TRAF7 associates with SCRIB (planar cell polarity protein) via its N-terminal region, while MEKK3 associates with the C-terminal WD40 domain. SCRIB and TRAF7 together mediate fluid shear stress-induced ERK5 phosphorylation in endothelial cells.\",\n      \"method\": \"Conditional knockout mouse (embryonic and endothelial-specific), Co-immunoprecipitation domain mapping of TRAF7-SCRIB and TRAF7-MEKK3, shear stress assays in cultured endothelial cells, ERK5/KLF2 Western blotting\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — knockout mouse with clear phenotype, domain-specific interaction mapping, and functional shear stress assays with multiple signaling readouts\",\n      \"pmids\": [\"37583551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRAF7 mutants (associated with meningioma/congenital heart defects) operate in a dominant-negative manner by heterodimerizing with wild-type TRAF7 protein. Somatic and inherited TRAF7 mutations disrupt TRAF7-IFT57 interactions, leading to cilia degradation. TRAF7 knockdown in Xenopus and zebrafish caused cardiac, craniofacial, and ciliary defects. TRAF7-mutant meningioma primary cultures lack cilia.\",\n      \"method\": \"Heterodimerization assay (dominant-negative mechanism), Co-IP of TRAF7-IFT57, primary culture ciliogenesis assay, TRAF7 morpholino knockdown in Xenopus and zebrafish\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods: heterodimerization, Co-IP interaction with IFT57, primary culture cilia assay, and in vivo vertebrate model knockdown\",\n      \"pmids\": [\"37043537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TRAF7 is an E3 ligase that forms a complex with E2 enzymes UBE2G1 and/or UBE2T to promote K48-linked polyubiquitination and proteasomal degradation of the circadian transcription factor DBP. TRAF7 knockout in NIH3T3 cells impairs time-of-day-dependent regulation of DBP levels, and TRAF7 overexpression shortens the circadian period.\",\n      \"method\": \"Proteomic analysis of DBP-interacting proteins, dominant-negative E2 screen (19 variants), Co-IP of TRAF7-UBE2G1/UBE2T-DBP complex, K48-specific ubiquitination assay, TRAF7 knockout in NIH3T3, circadian period assay\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — proteomic interactome, E2 enzyme screen, K48 ubiquitination assay, knockout with circadian phenotype — multiple orthogonal methods in one study\",\n      \"pmids\": [\"39379486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TRAF7 interacts with KLF4 and promotes its ubiquitin-mediated degradation. H2S S-sulfhydrates TRAF7 at Cys327, which weakens the TRAF7-KLF4 interaction and reduces ubiquitination of KLF4, thereby stabilizing KLF4 and upregulating VE-cadherin to protect endothelial barrier integrity. A TRAF7-Cys327 mutant mimicking S-sulfhydration recapitulated these protective effects.\",\n      \"method\": \"S-sulfhydration assay, Co-immunoprecipitation, ubiquitination assay, TRAF7-Cys327 mutagenesis, VE-cadherin expression/localization, endothelial permeability assay\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — site-specific mutagenesis (Cys327), S-sulfhydration assay, Co-IP, ubiquitination assay, and functional barrier assay in one focused study\",\n      \"pmids\": [\"38479633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The C. trachomatis effector Tri1 specifically interacts with TRAF7 during infection, recruits TRAF7 to the Chlamydia inclusion, and displaces native TRAF7 binding partners MEKK2 and MEKK3. The Tri1 coiled-coil domain is necessary for interaction with the TRAF7 WD40 domain. These findings confirm MEKK2 and MEKK3 as endogenous TRAF7 WD40-binding partners.\",\n      \"method\": \"Co-affinity purification, immunofluorescence confocal imaging, proteomics, domain deletion assays, infection-based interaction studies\",\n      \"journal\": \"Microbiology spectrum\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-affinity purification with proteomics, domain mapping, and imaging in infection context; single lab\",\n      \"pmids\": [\"38814079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRAF7 interacts with SOX12 protein and promotes K48-linked ubiquitination-mediated proteasomal degradation of SOX12 in esophageal squamous cell carcinoma cells. TRAF7's inhibitory effects on tumor cell proliferation and migration partly depended on SOX12, as shown by rescue experiments.\",\n      \"method\": \"Co-immunoprecipitation, K48-specific ubiquitination assay, rescue assay with SOX12 overexpression, cell proliferation and migration assays\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP, ubiquitination assay, and rescue experiment from a single lab with limited orthogonal validation\",\n      \"pmids\": [\"40623321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In vitro analyses of de novo germline TRAF7 missense mutations found in patients with developmental delay and congenital anomalies showed reduced ERK1/2 phosphorylation, indicating that TRAF7 promotes ERK1/2 signaling under normal conditions.\",\n      \"method\": \"In vitro expression of patient-derived TRAF7 mutants, Western blot for ERK1/2 phosphorylation\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single in vitro functional assay (phospho-Western), single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"29961569\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRAF7 is a RING finger–containing E3 ubiquitin ligase that uses its RING domain to catalyze predominantly K48-linked polyubiquitination (targeting substrates including TBK1, p53, KLF4, HOXA5, SOX12, and DBP for proteasomal degradation) and K29-linked ubiquitination of NEMO/p65 leading to lysosomal degradation, while its WD40 domain mediates protein–protein interactions with MEKK2, MEKK3, SCRIB, Robo4, and IFT57; through these interactions TRAF7 positions upstream in the shear stress–responsive MEKK3–MEK5–ERK5–KLF2 endothelial signaling axis, negatively regulates NF-κB by degrading NEMO and p65, represses c-Myb by cytoplasmic sequestration via sumoylation, promotes AP1/CHOP activation via MEKK3, cooperates with CYLD in a TLR2 feedback loop, regulates ciliogenesis via IFT57, controls circadian period via DBP turnover, and is a direct transcriptional target of MyoD1 that couples NF-κB activity to myogenesis; somatic mutations disrupting TRAF7 catalytic activity or its interaction with RAS GTPases activate CDC42/RAS signaling and drive meningioma and other tumor development, while germline dominant-negative mutations cause a developmental syndrome via heterodimerization with wild-type protein and loss of cilia.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRAF7 is a RING finger–containing E3 ubiquitin ligase that integrates protein-degradation control with scaffold-based signal transduction to regulate inflammatory signaling, endothelial homeostasis, and cellular growth [#0, #3]. Through its RING domain and a conserved catalytic cysteine, TRAF7 catalyzes ubiquitination of multiple substrates: it drives K48-linked polyubiquitination and proteasomal degradation of TBK1 (dampening IRF3/IFN-β antiviral responses) [#11], of the circadian transcription factor DBP in concert with the E2 enzymes UBE2G1/UBE2T to set circadian period [#14], and of tumor-suppressive or developmental transcription factors p53, KLF4, and SOX12 in cancer cells [#6, #10, #17]; it also promotes K29-linked ubiquitination of NEMO and p65/RelA, routing them to lysosomal degradation to repress NF-κB [#3, #4]. Its seven WD40 repeats mediate protein interactions—most notably with the MAP3Ks MEKK2 and MEKK3 [#0, #16]—placing TRAF7 upstream in the fluid shear stress–responsive MEKK3–MEK5–ERK5–KLF2 endothelial axis together with SCRIB, where its loss is embryonic lethal from impaired endothelial integrity [#12]. TRAF7 additionally supports endothelial barrier function via Robo4 and VE-cadherin stabilization [#7, #15] and negatively regulates c-Myb by promoting its sumoylation and cytoplasmic sequestration [#1]. Somatic loss-of-function mutations that disrupt catalysis or RAS-GTPase interaction activate CDC42/RAS signaling and drive meningioma and other tumors [#8], while dominant-negative germline mutations act through heterodimerization with wild-type protein and disrupt TRAF7–IFT57-dependent ciliogenesis, causing a developmental syndrome [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established TRAF7 as a domain-defined TRAF family member and linked it functionally to MAP3K signaling, answering what kind of protein it is and what pathway it engages.\",\n      \"evidence\": \"Co-IP, antisense depletion, domain mapping, and reporter assays showing MEKK3-dependent AP1/CHOP activation and apoptosis induction\",\n      \"pmids\": [\"15001576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish ubiquitin ligase substrates\", \"Apoptosis mechanism not resolved at the substrate level\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed TRAF7 acts as a transcriptional repressor of c-Myb through stimulation of sumoylation and cytoplasmic sequestration, and confirmed intrinsic E3 ligase activity via self-ubiquitination.\",\n      \"evidence\": \"Co-IP/domain mapping, in vitro sumoylation assay with site mutants, reporter assays, and subcellular fractionation\",\n      \"pmids\": [\"16162816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which TRAF7 stimulates sumoylation unclear\", \"Physiological context of c-Myb regulation not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed TRAF7 in TLR2-driven innate signaling alongside TRAF6 with CYLD as a negative regulator, broadening its role beyond MEKK3.\",\n      \"evidence\": \"Overexpression/reporter epistasis for NF-κB and p38 with TLR2 ligand stimulation\",\n      \"pmids\": [\"16230348\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reliance on overexpression rather than endogenous loss-of-function\", \"Direct CYLD-TRAF7 deubiquitination not shown biochemically\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified TRAF7 as a direct MyoD1 transcriptional target controlling NF-κB during myogenesis and identified NEMO as a TRAF7 interactor whose ubiquitylation depends on TRAF7.\",\n      \"evidence\": \"ChIP, siRNA depletion with differentiation assays, proteomic Co-IP screen, and ubiquitylation assays in myoblasts\",\n      \"pmids\": [\"20948544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin linkage type on NEMO not specified here\", \"Generality beyond muscle context unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a mechanism for TRAF7-mediated NF-κB repression via K29-linked ubiquitination and lysosomal degradation of NEMO and p65.\",\n      \"evidence\": \"Reciprocal Co-IP, K29-linkage-specific ubiquitination, lysosomal inhibitor rescue, and transcriptomic analysis\",\n      \"pmids\": [\"21518757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atypical K29 linkage mechanism not structurally explained\", \"In vivo relevance of lysosomal routing not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked tumor-associated WD40-domain mutations to gain of aberrant NF-κB activation, connecting genotype to a signaling output.\",\n      \"evidence\": \"WT vs mutant expression with p-NF-κB/L1CAM Westerns and IHC in adenomatoid tumors\",\n      \"pmids\": [\"29148537\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single in vitro system\", \"Mechanism connecting WD40 mutation to NF-κB activation not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Indicated TRAF7 normally promotes ERK1/2 signaling, since germline syndrome mutations reduce ERK1/2 phosphorylation.\",\n      \"evidence\": \"In vitro expression of patient-derived mutants with phospho-ERK1/2 Western blot\",\n      \"pmids\": [\"29961569\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single phospho-Western readout without mechanistic follow-up\", \"No endogenous or in vivo confirmation\", \"Relationship to ERK5 axis unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended TRAF7 substrate range to KLF4 in cancer, coupling its ligase activity to pro-metastatic motility.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, KLF4 rescue, and migration/invasion assays in vitro and in vivo\",\n      \"pmids\": [\"31730901\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin linkage on KLF4 not specified in this study\", \"Single tumor type\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed TRAF7 is required for Robo4-mediated protection of endothelial barrier integrity, establishing a vascular function.\",\n      \"evidence\": \"Reciprocal binding, deletion mapping, gain/loss-of-function, and Robo4 knockout mouse endotoxemia model\",\n      \"pmids\": [\"30510113\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRAF7 ligase activity is required downstream of Robo4 not resolved\", \"Direct effector of VE-cadherin stabilization not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined TRAF7 as a proteostatic regulator of RAS-related GTPases whose loss drives CDC42/RAS signaling and meningeal cell transformation, mechanistically explaining tumorigenic mutations.\",\n      \"evidence\": \"Ubiquitinome/proteome/interactome analysis, primary meningeal cell transformation model, and genetic epistasis with KLF4\",\n      \"pmids\": [\"34215617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct GTPase ubiquitination substrate(s) not fully enumerated\", \"How mutations selectively impair RAS interaction not structurally defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Confirmed TRAF7 acts upstream of MEKK3 in NF-κB/MAPK signaling in brain, with loss conferring neuroprotection after injury.\",\n      \"evidence\": \"Brain-specific conditional knockout, Co-IP, MEKK3 overexpression rescue, and OGD/R neuron-glia models\",\n      \"pmids\": [\"34953447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Role of ligase activity vs scaffold function in this context unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified p53 as a TRAF7 K48-ubiquitination substrate, explaining a route to its pro-tumorigenic activity in HCC.\",\n      \"evidence\": \"Co-IP, K48-specific ubiquitination assay, and p53-dependent rescue with phenotype assays\",\n      \"pmids\": [\"34775479\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single tumor system\", \"Relationship to KLF4 degradation in same cells not integrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated RING- and C131-dependent K48 ubiquitination of TBK1 by TRAF7, defining a negative regulatory node in antiviral IFN signaling.\",\n      \"evidence\": \"Co-IP, K48-specific ubiquitination, RING/C131 mutagenesis, knockout cells, and IRF3/IFN-β assays\",\n      \"pmids\": [\"37086853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo antiviral relevance not tested\", \"Regulation of TRAF7 activity during infection unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established TRAF7 as essential for endothelial integrity through the shear stress–responsive MEKK3–MEK5–ERK5–KLF2 axis, mapping SCRIB and MEKK3 to distinct TRAF7 regions.\",\n      \"evidence\": \"Conditional knockout mice with embryonic lethality, domain-specific Co-IP mapping, and shear stress assays with ERK5/KLF2 readouts\",\n      \"pmids\": [\"37583551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ubiquitin ligase activity is required for ERK5 activation unresolved\", \"Order of SCRIB/MEKK3 assembly on TRAF7 not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Explained the genetic mechanism of TRAF7-associated developmental syndrome and tumors through dominant-negative heterodimerization and disrupted IFT57-dependent ciliogenesis.\",\n      \"evidence\": \"Heterodimerization assay, TRAF7-IFT57 Co-IP, primary culture cilia assay, and morpholino knockdown in Xenopus and zebrafish\",\n      \"pmids\": [\"37043537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting IFT57 binding to cilia maintenance not detailed\", \"Whether ciliary defects underlie all syndrome features unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified TRAF7 as the E3 ligase, with UBE2G1/UBE2T, that controls DBP turnover and circadian period, extending its substrate repertoire to clock regulation.\",\n      \"evidence\": \"Proteomic interactome, E2 dominant-negative screen, Co-IP of the TRAF7-E2-DBP complex, K48 ubiquitination, and circadian period assay in knockout cells\",\n      \"pmids\": [\"39379486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TRAF7 activity is gated by time of day unknown\", \"Physiological circadian phenotype in vivo not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed that H2S-driven S-sulfhydration of TRAF7 at Cys327 inhibits KLF4 ubiquitination, defining a redox switch that stabilizes the endothelial barrier.\",\n      \"evidence\": \"S-sulfhydration assay, Co-IP, ubiquitination assay, Cys327 mutagenesis, and endothelial permeability/VE-cadherin assays\",\n      \"pmids\": [\"38479633\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous source/dynamics of H2S modification in vivo not established\", \"Interplay with C131 catalytic cysteine unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Confirmed MEKK2 and MEKK3 as endogenous WD40-binding partners of TRAF7 by showing a pathogen effector displaces them, validating the scaffold interface.\",\n      \"evidence\": \"Co-affinity purification, proteomics, confocal imaging, and domain deletion mapping in Chlamydia infection\",\n      \"pmids\": [\"38814079\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of MEKK displacement on host signaling not quantified\", \"Single pathogen system\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Added SOX12 as a K48-ubiquitination substrate of TRAF7 with tumor-suppressive consequences in esophageal squamous cell carcinoma.\",\n      \"evidence\": \"Co-IP, K48-specific ubiquitination, and SOX12-dependent rescue with proliferation/migration assays\",\n      \"pmids\": [\"40623321\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab with limited orthogonal validation\", \"Tissue-specificity of substrate choice unexplained\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how TRAF7 selects among its diverse substrates and switches between scaffold (MEKK2/3-ERK5) and catalytic (degradative) modes across tissues.\",\n      \"evidence\": \"No timeline study integrates the full substrate set with a unifying recruitment or regulatory logic\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of substrate recognition by the WD40/RING architecture\", \"Regulation of ubiquitin linkage choice (K48 vs K29) not mechanistically explained\", \"Tissue-specific determinants of substrate preference unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [1, 3, 11, 14]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 6, 10, 11, 14, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 8, 12]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 3, 11]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 11, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 13]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MAP3K3\", \"MAP3K2\", \"IKBKG\", \"RELA\", \"SCRIB\", \"ROBO4\", \"IFT57\", \"TBK1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}